Alzheimer's patients could lose out on two groundbreaking new drugs because the NHS is ... the first symptoms of dementia emerge, such as memory loss, or confusion. Donanemab and lecanemab are ...

Discover how dopamine’s unexpected role in breaking down harmful plaques could revolutionize Alzheimer's treatment and ...

Amnesia is a condition where a person experiences partial or complete memory loss, affecting their ability to recall past ...

More than six million Americans age 65 and up are living with Alzheimer’s including more than 35,000 Nebraska residents.

The federal Food & Drug Administration has approved two new Alzheimer’s medications ... antibody infusions for slowing memory and thinking loss. The FDA approved Lecanemab (Leqembi) in July ...

In addition to treating Alzheimer's disease, which affects roughly 6.9 million people over age 65 and has no known cure, VU319 has shown the potential to treat memory loss in schizophrenia ...